 Home > Medical News > Latest Medical News > AstraZeneca/Daisankyo ADC therapy plans to be included in the priority review of Class 1 new drugs introduced by Jingxin Pharmaceutical to submit the marketing application

AstraZeneca/Daisankyo ADC therapy plans to be included in the priority review of Class 1 new drugs introduced by Jingxin Pharmaceutical to submit the marketing application

 Last Update: 2022-05-12
 Source: Internet
 Author: User

Tags

cell culture company

ritalin side effects

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Breast cancer | AstraZeneca/Daiichi Sankyo ADC therapy proposed for priority review

Reviews

The clinical development of Enhertu is characterized by wide coverage and deep mining.

Insomnia disorder | Class 1 new drug introduced by Jingxin Pharmaceutical submitted a marketing application

Reviews

Andacini capsule is a partial positive allosteric modulator targeting gamma-aminobutyric acid A (GABAA) receptors for the treatment of insomnia disorders

Ulcerative colitis | Unknown Jun acquires UC drug candidate M201

On April 26, Unknown Jun announced that the company had acquired the clinical-stage M201 project from Assembly Biosciences

Reviews

It is reported that Unknown Jun has built an "AI+BT" platform that combines artificial intelligence, bioinformatics analysis and intestinal microecological technology to achieve "dry and wet combination" drug development

Biosimilars | Qilu Pharmaceutical's Aflibercept filed for listing

Reviews

Biological medicine is one of the important research fields of Qilu Pharma

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.